EGFR protein: Molecular mechanisms from ligand recognition to downstream signaling cascades
Author: Senior Product Manager of UA Views：9 
This article focuses on the molecular localization and signal transduction mechanisms of the epidermal growth factor receptor (EGFR), systematically elaborating its structural characteristics as a transmembrane glycoprotein and its chromosomal localization as a member of the HER family, analyzing the molecular process by which six ligands bind to the EGFR extracellular domain to induce dimerization and tyrosine kinase activation, and exploring the cascade logic through which activated EGFR transmits proliferation and anti-apoptotic signals to the nucleus via downstream pathways such as PI3K-AKT-mTOR and Ras-Raf-MEK-ERK1/2.
- Recent Advances
- Product Information
Recent Advances
EGFR Protein: Molecular Mechanisms from Ligand Recognition to Downstream Signaling Cascades
Brief Introduction: This article focuses on the molecular localization and signal transduction mechanisms of the epidermal growth factor receptor (EGFR), systematically elaborating on its structural features and chromosomal localization as a transmembrane glycoprotein member of the HER family, analyzing the molecular process by which six ligands bind to the EGFR extracellular domain to induce dimerization and tyrosine kinase activation, and discussing the cascade logic through which activated EGFR transmits proliferation and anti-apoptotic signals to the nucleus via downstream pathways such as PI3K-AKT-mTOR and Ras-Raf-MEK-ERK1/2.
I. Molecular Identity and Family Localization of EGFR.
The epidermal growth factor receptor (abbreviated as EGFR, ErbB-1, or HER1) is a multifunctional glycoprotein widely distributed on the cell membranes of various human tissues. In terms of gene localization, its gene is located on chromosome 7, region 7p12, and expression of this gene can be detected in various epithelial-derived tissues. EGFR is a member of the epidermal growth factor receptor family within receptor tyrosine kinases and is an important type of transmembrane receptor. Members of the HER family also include HER2 (erbB2, NEU), HER3 (erbB3), and HER4 (erbB4), which play important roles in cellular physiological processes such as proliferation and anti-apoptosis. This family configuration of "four homologous members with complementary functions" determines that the signal output of EGFR needs to be understood within the framework of family interactions——it can form homodimers as well as heterodimers with other family members, thereby producing differentiated downstream effects.
II. The Ligand System and Ligand Recognition Characteristics of EGFR.
A total of 6 EGFR ligands have been identified to date, primarily epidermal growth factor and transforming growth factor-α, as well as amphiregulin, β-cellulin, heparin-binding EGF-like growth factor, and epiregulin. The existence of this multi-ligand system gives EGFR activation multiple triggering pathways; different ligands differ in tissue distribution, expression regulation, and receptor affinity, thereby endowing EGFR signaling with adaptability and diversity under different physiological contexts. Ligand-receptor binding is not a simple "key-in-lock" interaction but induces conformational changes in the receptor extracellular domain that expose the dimerization interface; this conformational rearrangement is the structural prerequisite for receptor activation.
III. Ligand-Induced EGFR Dimerization and Kinase Activation.
When ligands such as epidermal growth factor and transforming growth factor-α bind to extracellular receptors, EGFR dimerization causes the intracellular domain to form activated tyrosine kinases. Specifically, the intracellular tyrosine kinase domain undergoes a biochemical reaction with ATP, ATP is converted to ADP, and tyrosine kinase phosphorylation activates EGFR enzyme activity. The molecular logic of this process can be summarized as a four-step cascade of "ligand binding—conformational change—dimerization—autophosphorylation," in which autophosphorylation is both a manifestation of kinase activity and a key step in providing docking sites for downstream signaling molecules. It should be noted that EGFR kinase activation strictly depends on ligand-induced dimerization; this "ligand-gated" mechanism is an important safeguard for normal cells to maintain precision in growth regulation.
IV. Cascade Transduction of EGFR Downstream Signaling Pathways.
Activated EGFR can transmit proliferation signals and anti-apoptotic signals to the nucleus through multiple downstream signal transduction pathways such as PI3K-AKT-mTOR and Ras-Raf-MEK-ERK1/2, controlling cell growth and division. These two core pathways are functionally complementary: the PI3K-AKT-mTOR pathway mainly mediates cell survival, metabolic reprogramming, and anti-apoptotic effects, while the Ras-Raf-MEK-ERK1/2 pathway mainly drives cell cycle progression and transcription of proliferation-related genes. The coordinated activation of the two pathways enables EGFR to simultaneously initiate two programs—"survive" and "grow"—after ligand stimulation, which also explains why dysregulated EGFR signaling simultaneously promotes abnormal proliferation and anti-apoptotic capacity in tumor cells. From a drug development perspective, the common node upstream of these two pathways is the EGFR kinase itself, so inhibition of kinase activity can simultaneously block both downstream branches, which is also the mechanistic basis for EGFR becoming a classic therapeutic target.
V. Conclusion.
As a transmembrane glycoprotein located on chromosome 7, region 7p12, and widely distributed in epithelial-derived tissues, EGFR—by virtue of its receptor network formed with HER2, HER3, and HER4 as a HER family member, its ligand-dependent dimerization activation mechanism mediated by six ligands including epidermal growth factor and transforming growth factor-α, and its cascade logic of transmitting proliferation and anti-apoptotic signals to the nucleus through the dual pathways of PI3K-AKT-mTOR and Ras-Raf-MEK-ERK1/2—has become one of the most representative molecules in the fields of receptor tyrosine kinase research and tumor-targeted therapy. From conformational rearrangement induced by ligand recognition to dimerization-driven autophosphorylation, from coordinated activation of dual pathways to the kinase node as the common upstream of therapeutic intervention, EGFR continues to drive in-depth development in the fields of signal transduction mechanism research and targeted drug development.
VI. Common Questions and Product Information for EGFR Binding Activity Detection
To facilitate the retrieval of evaluation schemes and product information for EGFR interactions by researchers and drug development teams, this section answers common questions about EGFR binding activity detection in a Q&A format and provides the product positioning and applicable scenarios of EGFR His Tag Protein, Human.
Q1: What methods are used to detect the binding activity of EGFR?
EGFR activation depends on ligand-induced dimerization, so its in vitro evaluation typically focuses on the direct binding of ligands (such as EGF and TGF-α) or targeted drugs to the EGFR extracellular domain. Currently, in vitro methods for evaluating this interaction mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), as well as time-resolved fluorescence resonance energy transfer (TR-FRET). Among these, ELISA and SPR/BLI can directly quantify the binding affinity of ligands or antibodies to the EGFR extracellular domain and are commonly used tools for ligand characterization studies and early screening of antibody drugs.
EGFR activation depends on ligand-induced dimerization, so its in vitro evaluation typically focuses on the direct binding of ligands (such as EGF and TGF-α) or targeted drugs to the EGFR extracellular domain. Currently, in vitro methods for evaluating this interaction mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) and biolayer interferometry (BLI), as well as time-resolved fluorescence resonance energy transfer (TR-FRET). Among these, ELISA and SPR/BLI can directly quantify the binding affinity of ligands or antibodies to the EGFR extracellular domain and are commonly used tools for ligand characterization studies and early screening of antibody drugs.
Q2: How does ELISA evaluate the binding activity of ligands or targeted antibodies to EGFR?
In a typical ELISA system, recombinant EGFR protein is coated in the wells of a microplate, gradient-diluted ligands (such as EGF) or candidate antibodies are added and incubated, and absorbance signals are read through enzymatic secondary antibodies or labeled ligands for color development. By plotting concentration against signal value, the half-maximal effective concentration (EC50) or linear detection range can be fitted to compare the binding capacity of different ligands or antibodies to EGFR. Since the EGFR protein carries a His tag, an anti-His antibody can also be used to capture EGFR and then detect the binding molecule, flexibly adapting to different experimental needs.
In a typical ELISA system, recombinant EGFR protein is coated in the wells of a microplate, gradient-diluted ligands (such as EGF) or candidate antibodies are added and incubated, and absorbance signals are read through enzymatic secondary antibodies or labeled ligands for color development. By plotting concentration against signal value, the half-maximal effective concentration (EC50) or linear detection range can be fitted to compare the binding capacity of different ligands or antibodies to EGFR. Since the EGFR protein carries a His tag, an anti-His antibody can also be used to capture EGFR and then detect the binding molecule, flexibly adapting to different experimental needs.
Q3: What is EGFR His Tag Protein, Human?
EGFR His Tag Protein, Human (Catalog No. UA010306) is a human-derived EGFR recombinant protein provided by UniOne (UA-Bio), expressed in the HEK293 expression system, with an expressed sequence of Leu25-Ser645 (Accession: P00533-1), a His tag at the C-terminus, and covering the EGFR extracellular domain, facilitating efficient purification through immobilized metal affinity chromatography. The product has a purity greater than 95% (dual verification by SDS-PAGE and HPLC) and is suitable for binding activity analysis of EGFR with ligands such as EGF and TGF-α, in vitro research on EGFR dimerization and kinase activation mechanisms, and screening and activity evaluation of antibody drugs and small-molecule inhibitors targeting EGFR.
EGFR His Tag Protein, Human (Catalog No. UA010306) is a human-derived EGFR recombinant protein provided by UniOne (UA-Bio), expressed in the HEK293 expression system, with an expressed sequence of Leu25-Ser645 (Accession: P00533-1), a His tag at the C-terminus, and covering the EGFR extracellular domain, facilitating efficient purification through immobilized metal affinity chromatography. The product has a purity greater than 95% (dual verification by SDS-PAGE and HPLC) and is suitable for binding activity analysis of EGFR with ligands such as EGF and TGF-α, in vitro research on EGFR dimerization and kinase activation mechanisms, and screening and activity evaluation of antibody drugs and small-molecule inhibitors targeting EGFR.
Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: binding activity analysis and EC50 determination of EGFR with ligands such as EGF and TGF-α; binding activity evaluation of monoclonal antibodies (such as cetuximab) and bispecific antibodies targeting EGFR; in vitro screening of small-molecule tyrosine kinase inhibitors targeting EGFR; in vitro research on EGFR dimerization and kinase activation mechanisms; and parallel comparison of binding activity among different ligands, antibodies, or protein batches.
The main application scenarios of this product include: binding activity analysis and EC50 determination of EGFR with ligands such as EGF and TGF-α; binding activity evaluation of monoclonal antibodies (such as cetuximab) and bispecific antibodies targeting EGFR; in vitro screening of small-molecule tyrosine kinase inhibitors targeting EGFR; in vitro research on EGFR dimerization and kinase activation mechanisms; and parallel comparison of binding activity among different ligands, antibodies, or protein batches.
Q5: What advantages does the His-tagged EGFR extracellular domain protein offer in experiments?
The His tag facilitates efficient purification through immobilized metal affinity chromatography, improving protein yield and purity; meanwhile, the His tag can serve as a capture or detection tag, allowing EGFR to be directionally immobilized on ELISA plates or SPR chip surfaces through anti-His antibodies, flexibly adapting to various experimental modes such as "protein coating—ligand/antibody detection" or "antibody capture—protein detection." Since this product is the EGFR extracellular domain (Leu25-Ser645), it retains the ligand recognition and dimerization interfaces and is suitable for evaluating ligand binding and antibody blocking activity in homogeneous or solid-phase systems without the need to handle the transmembrane region of the full-length receptor.
The His tag facilitates efficient purification through immobilized metal affinity chromatography, improving protein yield and purity; meanwhile, the His tag can serve as a capture or detection tag, allowing EGFR to be directionally immobilized on ELISA plates or SPR chip surfaces through anti-His antibodies, flexibly adapting to various experimental modes such as "protein coating—ligand/antibody detection" or "antibody capture—protein detection." Since this product is the EGFR extracellular domain (Leu25-Ser645), it retains the ligand recognition and dimerization interfaces and is suitable for evaluating ligand binding and antibody blocking activity in homogeneous or solid-phase systems without the need to handle the transmembrane region of the full-length receptor.
Product Information Overview
| Product Name | EGFR His Tag Protein, Human (Catalog No.: UA010306) |
| Brand | UniOne (UA-Bio) |
| Molecular Aliases | ERBB, ERBB1, HER1, PIG61, mENA |
| Accession | P00533-1 |
| Expressed Sequence | Leu25-Ser645 with His Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 100-130 kDa (Reducing) |
| Purity | >95% by SDS-PAGE & HPLC |
| Tag | His Tag |
| Form | Lyophilized powder |
| Buffer System | PBS, pH7.4, 5% trehalose |
| Reconstitution Method | After brief centrifugation, reconstitute with ultrapure water to 0.1-1 mg/mL according to the specification |
| Storage Conditions | Lyophilized powder stored at -20 to -80℃, stable for 12 months from the date of receipt; after reconstitution, store at -20 to -80℃ for 3 months or at 2 to 8℃ for 1 week under sterile conditions; avoid repeated freeze-thaw cycles |
| Core Applications | Quantitative binding activity analysis, ligand/antibody screening and activity evaluation, dimerization mechanism research, mechanism of action validation |
| Common Search Terms | EGFR binding activity detection, EGFR His Tag Protein, EGFR antibody screening, EGFR ligand binding, EGFR recombinant protein, UA010306, UniOne |
To conduct EGFR binding activity detection or activity evaluation of EGFR-targeted drugs, search for the full product name "EGFR His Tag Protein, Human" or the catalog number "UA010306" in the UniOne (UA-Bio) product center to obtain the product manual, experimental protocols, and supporting reagent information.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose 
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UNIV Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 苏ICP备2025207586号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
